| Identification | Back Directory | [Name]
Tulathromycin A | [CAS]
217500-96-4 | [Synonyms]
Draxxin
CS-2009
CP 472295
Teramycin
Tulamycin
Tulathrmycin A
TULATHROMYCIN A
Unii-897A3kn7ap
Tulathromycin A, >=95%
Tulathromycin isomer mix
Tulathromycin A USP/EP/BP
Tulathromycin A (CP 472295)
Tulathromycin，Tulathromycin A
Tulathromycin A Solution, 1000ppm
pharmaceutical ingredient TULATHROMYCIN A
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-13-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyl-5-(propylaminomethyl)oxan-2-yl]oxy-3,5,8,10,12,14-hexamethyl-1-oxa-6-azacyclopentadecan-15-one
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[[2,6-Dideoxy-3-C-Methyl-3-O-Methyl-4-C-[(propylaMino)Methyl]-α-L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexaMethyl-11-[[3,4,6-trideoxy-3-(diMethylaMino)-β-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[[2,6-Dideoxy-3-C-methyl-3-O-methyl-4-C-[(propylamino)methyl]-a-L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-b-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one
1-Oxa-6-azacyclopentadecan-15-one, 13-[[2,6-dideoxy-3-C-methyl-3-O-methyl-4-C-[(propylamino)methyl]-α-L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-2-ethyl-3,4,10-trihydroxy-13-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyl-5-((propylamino)methyl)tetrahydro-2H-pyran-2-yl)oxy)-3,5,8,10,12,14-hexamethyl-1-oxa-6-azacyclopentadecan-15-one | [EINECS(EC#)]
638-829-0 | [Molecular Formula]
C41H79N3O12 | [MDL Number]
MFCD09838804 | [MOL File]
217500-96-4.mol | [Molecular Weight]
806.084 |
| Chemical Properties | Back Directory | [Melting point ]
186-188oC | [Boiling point ]
853.8±65.0 °C(Predicted) | [density ]
1.17 | [storage temp. ]
Keep in dark place,Inert atmosphere,Store in freezer, under -20°C | [solubility ]
DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
13.19±0.70(Predicted) | [color ]
White to Off-White |
| Hazard Information | Back Directory | [Chemical Properties]
White Solid | [Description]
Tulathromycin A is a triamide antibiotic used for the treatment of respiratory diseases in cattle and pigs. It exists as a balanced mixture of two isomers. Tulathromycin is an antimicrobial agent of a macrolide, a 15-membered macrolide structure that is considered a triamide macrolide with three charged nitro groups. | [Uses]
Triamilide antibiotic for treatment of bovine and porcine respiratory disease. Exists as an equilibrium mixture of two isomeric forms, Tulathromycin A (90%) and B (10%). Antibacterial. | [Uses]
Tulathromycin is a semi-synthetic erythromycin belonging to the ring expanded aza–erythromycins. Ring expansion improvedsthe acid lability of the parent erythromycins. Tulathromycin is regarded as the first of the triamilides, having a third amino (propylaminomethylene) group on a sugar to improve absorption. This modification provides a mixture of the two tulathromycin isomers (90:10) present in the commercial animal health product. | [Uses]
Tulathromycin is a semi-synthetic erythromycin belonging to the ring expanded aza–erythromycins. Ring expansion improves the acid lability compared with the parent erythromycins. Tulathromycin is regarded as the first of the triamilides, having a third amino (propylaminomethylene) group on a sugar to improve absorption. This modification provides a mixture of the two tulathromycin isomers (90:10) present in the commercial animal health product. | [Definition]
ChEBI:Tulathromycin A is an aminoglycoside. | [Biological Activity]
Tulathromycin, like other macrolides, exerts therapeutic benefits not solely explainable by antibacterial activity. Like azithromycin, tulathromycin A may have multiple immunomodulatory effects that likely contribute to the therapeutic response in respiratory infections and perhaps other diseases[1]. Other beneficial effects may be caused by enhanced degranulation and apoptosis of neutrophils and inhibition of inflammatory cytokine production. It also may help clear infections by enhancing macrophage functions. | [Pharmacokinetics]
The half-life is long, with 80- to 90-hour plasma half-life in pigs and cattle, and 8- and 6-day tissue half-life in cattle and pigs, respectively, which prolongs the drug concentration at the site of infection. The volume of distribution is greater than 10 L/kg. Absorption from injection is greater than 80% in cattle and pigs. Tulathromycin A concentrates in bronchoalveolar cells, and concentrations are detectable for at least 8 days after a single administration, although they are still lower than the MIC for R. equi (greater than 64 μg/mL)[1-2]. | [Mode of action]
Tulathromycin A is a macrolide antibiotic. It binds to the subunit 50S of the bacterial ribosome, interfering with bacterial protein synthesis. | [References]
[1] Mark G, et al. Tulathromycin. Papich Handbook of Veterinary Drugs (Fifth Edition), 2021; 949-951.
[2] Jennifer L, et al. Pharmacologic Principles. Equine Internal Medicine (Fourth Edition), 2018; 79-137. |
|
|